Tag: bioCSL global influenza vacine industry
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
All eyes on Melbourne as Australian Manufacturing Week prepares to open doors
In just four weeks, the spotlight will shine on Australia’s industrial heart as Australian Manufacturing Week 2025 (AMW) takes over Melbourne’s Convention and Exhibition Centre for four days of cutting-edge tech, world-class innovation, and industry-defining conversations.
